BioMarin Pharmaceutical-BioMarin's First-Quarter Earnings & Sales Beat Estimates

BioMarin Pharmaceutical (BMRN) reported first-quarter 2025 adjusted earnings per share of $1.13, which beat the Zacks Consensus Estimate of 94 cents. Quarterly earnings rose 59% year over year, driven by higher product sales and lower operating expenses.Total revenues were$ 745 million, which rose 15% year over year on a reported basis and 17% on a constant-currency basis. The top line beat the Zacks Consensus Estimate of $737 million. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar) ...